From the Society for Immunotherapy of Cancer
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:
On December 6, 2018, the Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech, Inc.), in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.
Approval was based on the IMpower150 trial (NCT02366143), an open-label, randomized (1:1:1), three-arm trial enrolling 1202 patients receiving first-line treatment for metastatic NSq NSCLC. Eighty-seven percent (1045 patients) were identified as not having EGFR or ALK tumor mutations. The trial was designed to conduct comparisons between each of the atezolizumab-containing arms with the control arm. Patients were randomized to receive the following:
- Atezolizumab, carboplatin, paclitaxel, and bevacizumab (4-drug regimen);
- Atezolizumab, carboplatin and paclitaxel (3-drug regimen); or
- Carboplatin, paclitaxel, and bevacizumab (control arm).
Following completion of 4 or 6 cycles of carboplatin and paclitaxel, patients continued to receive bevacizumab in the 4-drug arm and the control arm and continued to receive atezolizumab in the two experimental arms until disease progression or unacceptable toxicity. The major efficacy measures were overall survival (OS) and progression-free survival (PFS).
Among patients with NSq NSCLC without an EGFR or ALK mutation, the estimated median OS was 19.2 months for patients receiving the 4-drug regimen and 14.7 months for those receiving, carboplatin, paclitaxel, and bevacizumab (hazard ratio [HR] 0.78; 95% CI: 0.64, 0.96; p=0.016). The estimated median PFS was 8.5 months for patients receiving the 4-drug regimen and 7.0 months for those in the control arm (HR 0.71; 95% CI 0.59, 0.85; p=0.0002). The overall response rates were 55% in the 4-drug arm and 42% in the control arm. No significant differences in interim OS or final PFS were observed between the 3-drug arm and the control arm.
The most common adverse reactions (reported in greater than or equal to 20% of patients) with atezolizumab administered with carboplatin, paclitaxel, and bevacizumab were fatigue/asthenia, alopecia, nausea, diarrhea, constipation, decreased appetite, arthralgia, hypertension, and neuropathy. Atezolizumab was discontinued for adverse reactions in 15% of patients; the most common adverse reaction resulting in discontinuation of atezolizumab was pneumonitis (1.8%).
The incidence of development antibodies to atezolizumab (anti-drug antibodies, ADA) ranges from 30% to 42% across clinical studies supporting the approved indications. Among 364 patients with NSCLC who received the 4-drug regimen in the IMpower150 study, 36% (n=132) had treatment-emergent antibodies against atezolizumab with the majority (83% of these 132 patients) having ADA prior to receiving the second atezolizumab dose. Patients who tested positive for treatment-emergent ADA had lower systemic atezolizumab exposure compared to those who were ADA negative. In an exploratory analysis, the HR for OS was similar in the ADA-positive (0.69; 95% CI: 0.44, 1.07) and the ADA-negative subgroups (0.64; 95% CI: 0.46, 0.90). The presence of ADA neither increased the incidence nor severity of adverse reactions. Given the high rate of ADA, Genentech has agreed to conduct analyses across the atezolizumab development program to evaluate the effects of ADA on efficacy, safety, and pharmacokinetics.
The recommended atezolizumab dose is 1200 mg intravenously over 60 minutes every 3 weeks.
View full prescribing information for TECENTRIQ.
FDA granted this application priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.